The interview introduces the investigator and study coordinator to referring physicians. The host asks the questions remotely, and each answer is recorded separately from an agreed script. The video uses clear captions and simple study graphics rather than a podcast introduction.
Before recording
- Current protocol, informed consent form and investigator brochure confirmed
- Eligibility wording checked against the current protocol
- Sponsor's required safety summary included in the spoken script
- Investigator's title, site name and personal remarks confirmed by the investigator
- Sponsor approves the script first, then the recording; IRB reviews the materials before use
- Referral route and communication plan with referring offices agreed with the site
Message guardrails
- Describe the study. Make no claims about the safety or efficacy of an investigational therapy.
- Do not suggest that taking part offers convenience or a proven benefit. Individual benefit is not guaranteed.
- No sponsor names, product names or comparisons in the spoken script.
- Present patient features as preliminary points to discuss with the study team, never as eligibility.
- Keep patient information out of every conversation and every reply.
The interview
·
Opening
On screen Host, investigator and site on screen as lower thirds
HostIf a patient continues to have symptoms despite standard oral treatment, when might a research referral be worth discussing? I'm Shubhalok Ghosh, speaking with Dr. [Name], a [specialty] in [city], about a study for adults with an uncontrolled chronic condition. We'll cover the patient profile, what participation involves, and how to reach the study team.
1
Introducing the investigator
On screen Name, specialty and site
HostDr. [Name] has spent [number] years building a clinical research program in [city] and has helped complete more than [number] clinical trials. Today, Dr. [Name] is inviting more community physicians into that work. What have those years in research taught you, and why do you want more community physicians involved?
InvestigatorWhat keeps me involved is the patient whose condition continues to disrupt everyday life. Another flare can mean another interruption to work, mobility or daily activities. Community practice has an important part to play in answering those questions.
InvestigatorMy colleagues know their patients well. I want them to have a research colleague they can call, someone who can explain a study, discuss a potential candidate and clarify what participation would involve. My aim is to give appropriate patients the opportunity to consider research, and to help generate evidence that may inform future care.
2
The research question
On screen Investigational study | Randomized, double blind | Two routes of administration
HostWhat is the study designed to evaluate?
InvestigatorThis is a Phase [3], randomized, double blind study in adults with an uncontrolled chronic condition. It compares the safety and efficacy of an investigational therapy given by two different routes. The larger question is whether we can expand the options available to people whose condition remains uncontrolled.
InvestigatorOur role is to help generate the evidence needed to understand how the two routes compare. Benefit for an individual participant is not guaranteed.
3
The patient profile
On screen Adults 18 or older | Persistent symptoms despite standard treatment | Other criteria apply
HostWhich patients should a referring physician have in mind?
InvestigatorThe starting point is an adult with persistent symptoms despite conventional oral treatment, or who cannot tolerate it. There are specific clinical measures and history requirements, and they are best reviewed with our study team. What I am describing are preliminary features to discuss. They do not establish eligibility.
Recording hold: check every clinical value against the current protocol before this answer is recorded.
4
When a referral may not be suitable
On screen Prior treatment and current medicines require review | Full review by the site | Not a complete list
HostWhat should physicians check before considering a referral?
InvestigatorPlease discuss prior treatment history with our study team, because some earlier therapies affect suitability. Other medical conditions, organ function and current medicines also need review, and the full protocol has additional requirements.
InvestigatorPlease do not stop or change a patient's medication solely to prepare for a referral. Medication decisions need to be coordinated with the study team.
5
What randomization means
On screen Both groups receive active treatment | No placebo-only group
HostHow are the two study groups treated?
InvestigatorAn important feature of this study is that both randomized groups receive active treatment. No group receives placebo alone. Participants cannot choose their group, and the study team explains clearly what each group involves.
InvestigatorFor referring physicians, this means an appropriate patient may consider a study in which active treatment is part of either assignment. Individual benefit is not guaranteed, and the study team will discuss eligibility, risks and participation requirements with each potential participant.
6
Participation and uncertainty
On screen Screening | Preparation | Treatment visits | Safety follow-up
Host[Coordinator], what time and visit commitment should physicians keep in mind when discussing a possible referral?
CoordinatorParticipation has several stages: screening, a preparation period for those who qualify, a treatment period with regular visits, and safety follow-up. Some visits can be long. Our team reviews the full schedule with each patient so they can decide whether participation is right for them.
HostDr. [Name], what should patients understand about the risks and the uncertainty of taking part?
InvestigatorStudy treatment and procedures carry risks, including reactions and other possible side effects. Participation may or may not help a patient's condition. Their health could improve, stay the same or worsen. Before anyone decides, our team reviews the informed consent, including the risks, alternatives and participant rights. Participation is voluntary.
Recording hold: replace or expand the safety paragraph with the sponsor's required summary. This sample is not a complete risk disclosure.
7
Working with the referring practice
On screen The referring physician continues routine care
Host[Coordinator], if a physician has a patient in mind, what happens next, and how does the referring practice stay involved?
CoordinatorWe welcome a conversation with the physician before any referral is made. We can explain the requirements and answer questions about the process. If the patient is interested in learning more, our team can discuss screening and informed consent with them.
CoordinatorThe referring physician continues to manage routine care, and our team handles study care. We agree on communication with the referring office from the outset, and any patient records are shared through a secure process.
8
Closing
On screen Study team contact details appear on screen
HostDr. [Name], what would you say to colleagues considering a research partnership with your team?
InvestigatorI would welcome the opportunity to work together. If we already know one another, I hope this study opens a new chapter in that relationship. If we haven't worked together before, this could be the beginning of a research partnership.
InvestigatorMy hope is to build stronger connections across our medical community, so more patients can learn about research opportunities that may be appropriate for them. For colleagues who would like to learn more, the contact information for my research team appears on screen at the end of this video.